Trichosporon austroamericanum

Trichosporon austroamericanum
Scientific classification Edit this classification
Kingdom: Fungi
Division: Basidiomycota
Class: Tremellomycetes
Order: Trichosporonales
Family: Trichosporonaceae
Genus: Trichosporon
Species:
T. austroamericanum
Binomial name
Trichosporon austroamericanum
Francisco et al., 2024

Trichosporon austroamericanum is an anamorphic basidiomycetous yeast species with opportunistic pathogenic potential, formally described in 2024.[1] It was long confused with Trichosporon inkin due to their close phylogenetic relationship,[1] but is now recognized as the second most frequently implicated Trichosporon species in invasive trichosporonosis in France.[2]

Etymology

The species name austroamericanum derives from the Latin austro- ("southern") and americanum ("American"), referring to South America, where the first identified strain originated.[1]

History

Discovery

The first strain of T. austroamericanum was isolated in 2013 in Brazil from the urine of a 15-year-old renal transplant patient undergoing surgery for a urinary fistula.[1] The isolate was initially identified as Trichosporon inkin due to strong phenotypic and molecular similarity between the two species.[1]

Recognition as a distinct species

In 2024, Francisco et al. formally described T. austroamericanum as a new species based on detailed phylogenetic analysis.[1] The historical confusion with T. inkin is explained by their genetic proximity, which makes differentiation difficult using routine molecular tools.[1]

In 2025, the first complete genome sequencing of T. austroamericanum (type strain CBS 17435) was performed using long-read Nanopore sequencing technology.[3] Average Nucleotide Identity (ANI) between T. austroamericanum and T. inkin was 84.64%, well below the 95% threshold commonly used for species delimitation, confirming that they are distinct species.[3] These findings were supported by comparative genomic analysis of three Japanese clinical isolates.[4]

Description

Morphology

T. austroamericanum is an anamorphic (asexual) fungus that presents as a yeast. Like other species of Trichosporon, it produces arthroconidia through hyphal fragmentation.[1] Its morphology is very similar to that of T. inkin, making differentiation difficult using conventional microscopic or macroscopic examination.[1]

Differentiation from T. inkin

Differentiation relies mainly on molecular methods, including sequencing of the IGS1 (Intergenic Spacer 1) region and multilocus phylogenetic analysis. Phenotypic differences include thermotolerance (growth at 45 °C), absence of growth in media containing 50% glucose, and inability to utilize succinate or citrate.[1]

Ecology

The environmental reservoir of T. austroamericanum remains unknown.[1] Like other Trichosporon species, it is part of the transient human microbiota and may colonize the skin and gastrointestinal tract without causing disease in immunocompetent individuals.[1]

Epidemiology

Global distribution

Strains of T. austroamericanum—initially misidentified as T. inkin—have been reported worldwide, suggesting a cosmopolitan distribution:[1][2]

  • Brazil (blood cultures)[1]
  • China (invasive infections)[1]
  • Thailand (urinary isolates)[2]
  • India (superficial mycoses)[1]
  • France and Argentina (various clinical cases)[1]

Prevalence in France

A French study (2002–2022) found that T. austroamericanum accounted for 22.8% of Trichosporon isolates, making it the second most frequently identified species in the country.[2]

Another study reidentified 17 isolates initially classified as T. inkin as T. austroamericanum using IGS1 sequencing.[5]

Clinical characteristics

At-risk populations

Invasive infections mainly occur in immunocompromised patients or those undergoing major surgery.[2] In a French cohort (21 cases):

  • 86.4% were male
  • 36.4% had recent surgery
  • 36.4% were solid organ transplant recipients

Clinical manifestations

Reported infection sites include:[2]

  • fungemia: 68.2%
  • bone infections: 18.2%
  • cutaneous infections: 4.5%

Prognosis

The 30-day mortality rate was 22.7% in the studied cohort.[2]

European surgical context

A fatal case following heart transplantation has been reported, initially misidentified as T. inkin.[5] Literature review highlights similar invasive infections after major thoracic surgeries in Europe.[5]

Persistent fever in immunocompromised patients receiving echinocandin therapy may suggest infection with resistant Trichosporon species.[5]

Virulence factors

Identified virulence factors include:[4]

Diagnosis

Identification is challenging due to frequent confusion with T. inkin.[1] Reliable methods include:

  • IGS1 region sequencing (reference method)[1][5]
  • updated MALDI-TOF databases including reference spectra[2]
  • whole-genome sequencing (Nanopore), confirming species distinction via ANI[3]

Antifungal susceptibility

Antifungal susceptibility (EUCAST, 21 isolates):[2]

AntifungalMIC50 (mg/L)MIC90 (mg/L)Range (mg/L)
Voriconazole0.030.06<0.015–0.125
Posaconazole0.060.25<0.015–0.25
Amphotericin B0.2510.06–2
Flucytosine>64>6464–>64
Fluconazole0.540.25–4

T. austroamericanum is intrinsically resistant to echinocandins. New-generation triazoles (voriconazole, posaconazole, isavuconazole) show the best in vitro activity.[2]

Voriconazole is the recommended first-line treatment.[2]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Francisco, E.C.; Desnos-Ollivier, M.; Dieleman, C.; Boekhout, T.; Santos, D.W.C.L.; Medina-Pestana, J.O.; Colombo, A.L.; Hagen, F. (2024). "Unveiling Trichosporon austroamericanum sp. nov.: A novel emerging opportunistic basidiomycetous yeast species". Mycopathologia. 189 (3): 43. doi:10.1007/s11046-024-00851-4. PMC 11074034. PMID 38709328.
  2. 1 2 3 4 5 6 7 8 9 10 11 Desnos-Ollivier, M. (2026). "Clinical manifestations of emerging Trichosporon spp. infections, France". Emerging Infectious Diseases. 32 (1): 93–102. doi:10.3201/eid3201.250504. PMC 12870045. PMID 41612557.
  3. 1 2 3 Francisco, E.C.; Desnos-Ollivier, M.; Gerrits van den Ende, B.; Hagen, F. (2025). "De novo genome assembly and comparative genome analysis of the novel human fungal pathogen Trichosporon austroamericanum type-strain CBS 17435". Mycopathologia. 190 (2): 33. doi:10.1007/s11046-025-00942-w. PMC 11971232. PMID 40183900.
  4. 1 2 Horiguchi, T.; Umeyama, T.; Tomuro, H. (2025). "Whole-genome sequencing and comparative genomic analysis of three clinical bloodstream infection isolates of Trichosporon austroamericanum". Journal of Fungi. 11 (5): 401. doi:10.3390/jof11050401. PMC 12113199. PMID 40422735.
  5. 1 2 3 4 5 Cordier, C. (2026). "Invasive Trichosporon austroamericanum infection following heart transplantation: a case report and literature review of Trichosporon inkin sensu lato infections after thoracic surgery". Journal of Medical Mycology. 36 (1) 101600. doi:10.1016/j.mycmed.2026.101600. PMID 41547089.